BNP Paribas Financial Markets Buys Shares of 3,895 Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

BNP Paribas Financial Markets purchased a new stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 3,895 shares of the company’s stock, valued at approximately $48,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Mineralys Therapeutics by 5.0% in the 4th quarter. Vanguard Group Inc. now owns 1,432,042 shares of the company’s stock valued at $17,628,000 after acquiring an additional 68,811 shares during the period. Jennison Associates LLC increased its holdings in shares of Mineralys Therapeutics by 55.4% in the 4th quarter. Jennison Associates LLC now owns 1,082,006 shares of the company’s stock valued at $13,319,000 after acquiring an additional 385,726 shares during the period. Caligan Partners LP increased its holdings in shares of Mineralys Therapeutics by 3.1% in the 4th quarter. Caligan Partners LP now owns 1,011,155 shares of the company’s stock valued at $12,447,000 after acquiring an additional 30,000 shares during the period. ADAR1 Capital Management LLC increased its holdings in shares of Mineralys Therapeutics by 15.4% in the 4th quarter. ADAR1 Capital Management LLC now owns 841,541 shares of the company’s stock valued at $10,359,000 after acquiring an additional 112,140 shares during the period. Finally, Boothbay Fund Management LLC increased its holdings in shares of Mineralys Therapeutics by 7.3% in the 4th quarter. Boothbay Fund Management LLC now owns 650,023 shares of the company’s stock valued at $8,002,000 after acquiring an additional 44,067 shares during the period. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on MLYS shares. Guggenheim set a $48.00 price target on Mineralys Therapeutics and gave the company a “buy” rating in a report on Wednesday, May 14th. Wall Street Zen upgraded Mineralys Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. The Goldman Sachs Group cut their price target on Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Finally, HC Wainwright restated a “buy” rating and set a $42.00 target price on shares of Mineralys Therapeutics in a research note on Tuesday, May 13th.

Mineralys Therapeutics Price Performance

Shares of MLYS stock opened at $16.18 on Wednesday. Mineralys Therapeutics, Inc. has a 1-year low of $8.24 and a 1-year high of $18.38. The stock’s fifty day moving average price is $14.42 and its 200 day moving average price is $12.67. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -4.45 and a beta of -0.30.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Monday, May 12th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.23. As a group, equities research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Insider Buying and Selling

In other Mineralys Therapeutics news, CEO Jon Congleton sold 15,319 shares of the business’s stock in a transaction dated Friday, April 11th. The stock was sold at an average price of $12.19, for a total transaction of $186,738.61. Following the sale, the chief executive officer now owns 862,289 shares in the company, valued at approximately $10,511,302.91. The trade was a 1.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Adam Scott Levy sold 10,757 shares of the business’s stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $12.06, for a total value of $129,729.42. Following the completion of the transaction, the chief financial officer now directly owns 215,340 shares of the company’s stock, valued at approximately $2,597,000.40. This trade represents a 4.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 104,579 shares of company stock worth $1,534,353 in the last ninety days. 25.56% of the stock is owned by insiders.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.